ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient outcomes"

  • Abstract Number: 2910 • 2018 ACR/ARHP Annual Meeting

    Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials

    Liana Fraenkel1, W. Benjamin Nowell2, Carole Wiedmeyer2, Zhenglin Wei3, Kaleb Michaud4, Tuhina Neogi5, Christine Ramsey1 and David Broniatowski3, 1Yale University School of Medicine, New Haven, CT, 2Global Healthy Living Foundation, Upper Nyack, NY, 3George Washington University, Washington, DC, 4Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment…
  • Abstract Number: 594 • 2018 ACR/ARHP Annual Meeting

    Identification of Tocilizumab Treated RA Patients, Whom Are Not Likely to Show Long-Term Clinical Benefit; Reanalysis of the Biomarker Sub-Study of LITHE

    Anne C. Bay-Jensen1, Christian S. Thudium1, Claus Christiansen2 and Morten A. Karsdal1, 1Nordic Bioscience, Herlev, Denmark, 2Nordic Bioscience, Clinical Development, Herlev, Denmark

    Background/Purpose: Tocilizumab, anti-interleukin 6 receptor (IL-6R) therapy, is an effective treatment of rheumatoid arthritis (RA). However, a significant amount of patients do not respond adequately…
  • Abstract Number: 1387 • 2018 ACR/ARHP Annual Meeting

    Fatigue in Patients with Rheumatoid Arthritis As Compared to Different Groups of Cancer Patients

    Jens Gert Kuipers1, Michael Koller2, Ulrich Rueffer3, Florian Zeman2, Karolina Mueller4 and Joachim Weis5, 1Clinic for Internal Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, 2Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3German Fatigue Society, Cologne, Germany, 4Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 5University Clinic Centre Freiburg, Freiburg, Germany

    Background/Purpose: Fatigue is a common symptom in patients with rheumatoid arthritis (RA) as well as patients with cancer. Fatigue considerably reduces the quality of life…
  • Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting

    Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice

    Rubén Queiro1, Juan Cañete2, Carlos Alberto Montilla-Morales3 and Miguel A. Abad4, 1Rheumatology Division, HUCA, Oviedo, Spain, 2Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, 3Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, 4FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain

    Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…
  • Abstract Number: 1392 • 2018 ACR/ARHP Annual Meeting

    Decreased Injection Site Pain Associated with New Etanercept Formulation in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

    Stanley Cohen1, Ahmed Samad2, Elaine Karis2, Bradley S. Stolshek2, Mona Trivedi2, Hao Zhang2, Girish A. Aras2, Greg Kricorian2 and James Chung2, 1Metroplex Clinical Research Center, Dallas, TX, 2Amgen Inc., Thousand Oaks, CA

    Background/Purpose: Injection site pain (ISP) is a component of the patient experience with injectable drugs. A new formulation of etanercept was developed to reduce ISP.…
  • Abstract Number: 1407 • 2018 ACR/ARHP Annual Meeting

    Differences in the Measurement Properties of the Patient-Reported Outcomes Measurement Information System Physical Function Short-Form 10a Among Racial/Ethnic Minorities with Rheumatoid Arthritis

    Zara Izadi1, Patricia Katz2, Gabriela Schmajuk3, Julie Gandrup4, Jing Li5, Milena Gianfrancesco6 and Jinoos Yazdany7, 1Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, 2University of California San Francisco, San Francisco, CA, 3Medicine/Rheumatology, University of California - San Francisco, San Francisco, CA, 4Rheumatology, Odense University Hospital, Odense, Denmark, 5Medicine, UC San Francisco, San Francisco, CA, 6Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7University of California, San Francisco, San Francisco, CA

    Background/Purpose: Most studies evaluating patient-reported outcomes such as the PROMIS Physical Function Short Form 10a (PF10a) in rheumatoid arthritis (RA) have been performed in white…
  • Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting

    Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry

    Philip J. Mease1, Mei Liu2, Sabrina Rebello3, Winnie Hua2, Robert R. McLean2, Peter Hur4 and Alexis Ogdie5, 1Swedish Medical Center and University of Washington, Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Southborough, MA, 4Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
  • Abstract Number: 1643 • 2018 ACR/ARHP Annual Meeting

    Psa Impact of Disease Questionnaire Scores Are Correlated with Disease Activity, As Measured By Cdapsa in Patients with Psa

    Ana-Maria Orbai1, Klaus Krüger2, Frank Behrens3, Uta Kiltz4, Benoit Guerette5, Lillian Mellars5, Michele Brunori5 and Jürgen Wollenhaupt6, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Medical Centre of Rheumatology, Munich, Germany, 3Clinical Research Rheumatology and Fraunhofer Institute IMETranslation, Goethe University, Frankfurt, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Celgene Corporation, Summit, NJ, 6Schön-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany

    Background/Purpose: We examined clinical correlations between disease activity, as measured with the Clinical Disease Activity for PsA (cDAPSA) components and PsA life impact/health-related quality of…
  • Abstract Number: 1689 • 2018 ACR/ARHP Annual Meeting

    Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus

    Nathaniel J. Harris1, Amanda M. Eudy2 and Megan E. B. Clowse2, 1Department of Medicine, Duke University, Durham, NC, 2Department of Medicine, Division of Rheumatology and Immunology, Duke University, Durham, NC

    Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus Background/Purpose: Patient-reported measures of disease activity provide useful adjuncts to…
  • Abstract Number: 2293 • 2018 ACR/ARHP Annual Meeting

    Subcutaneous Intravenous Immunoglobulins in Idiopathic Inflammatory Myopathies: Analysis of a Monocentric Cohort

    Emanuele Calabresi1, Simone Barsotti2, Elisa Cioffi3, Alessandra Tripoli1, Andrea Delle Sedie1, Laura Bazzichi4, Ornella Mazzarella1, Rossella Neri4 and Marta Mosca1, 1Rheumatology Unit, University of Pisa, Pisa, Italy, 2Department of Medical Biotechnologies, University of Siena, Siena, Italy, 3Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, 4Rheumatology Unit, University of Pisa, PISA, Italy

    Background/Purpose: Despite the absence of specific guidelines, the treatment with intravenous immunoglobulins (IvIg) is considered effective in patients with refractory idiopathic inflammatory myopathies (IIM). Recently,…
  • Abstract Number: 2359 • 2018 ACR/ARHP Annual Meeting

    Systemic Lupus Erythematous Outcome Concerns: Identifying Pain As the Major Discrepancy between Rheumatologists and Patients

    Isabela Bertoglio1, Glaucia Abrahão1, Eloisa Bonfa2 and Michelle Lopes3, 1Rheumatology, Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, 3Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Now-a-days there is a growing trend of switching to a more patient-centered healthcare system, with a widespread use of patient-reported outcomes (PROs). However, most…
  • Abstract Number: 337 • 2017 ACR/ARHP Annual Meeting

    Patient-Reported Flares Were Correctly Predicted By an Algorithm Using Machine-Learning Statistics on Activity Tracker Data on Steps, in a Longitudinal 3-Month Study of 170 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA)

    Laure Gossec1, Frédéric Guyard2, Didier Leroy3, Thomas Lafargue2, Michel Seiler3, Charlotte Jacquemin1, Anna Molto4, Jeremie Sellam5, Violaine Foltz1, Frédérique Gandjbakhch1, Christophe Hudry6, Stéphane Mitrovic1, Bruno Fautrel1 and Herve Servy7, 1UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, 2IMT, Orange, Nice, France, 3Healthcare, Orange, Paris, France, 4Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, 5Rheumatology, Saint-Antoine Hospital, Paris, France, 6AP-HP Hôpital Cochin, Paris, France, 7e-health services, Sanoia, Gemenos, France

    Background/Purpose: The natural history of RA and axSpA comprises periods of low disease activity and flares. However, there are few data linking patient-reported flares to…
  • Abstract Number: 2535 • 2017 ACR/ARHP Annual Meeting

    Patient Outcomes from a Tertiary Center Combined Rheumatology-Dermatology Clinic

    Charis Gn1, Delaney Conway2, Joanne Cunha3, Abrar Qureshi4, So Yeon Paek5 and Anthony M. Reginato6, 1Division of Rheumatology, The Warren Alpert Medical School of Brown University, Providence, RI, 2Internal Medicine, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, 3Division of Rheumatology, The Warren Alpert Medical School of Brown University, East Providence, RI, 4Dermatology, Rhode Island Hospital, The Warren Alpert Medical School of Brown University, Providence, RI, 5Departmet of Dermatology, The Warren Alpert Medical School of Brown University, Providence, RI, 6Rhode Island Hospital, The Warren Alpert School of Medicine at Brown University, Providence, RI

    Background/Purpose: Many autoimmune diseases have both musculoskeletal and cutaneous manifestations, which historically have been managed separately by rheumatologists and dermatologists. Given the complex presentation of…
  • Abstract Number: 358 • 2017 ACR/ARHP Annual Meeting

    Patients and Physicians Have Different Perceptions of the Relative Bother of the Symptoms and Impacts on Daily Activities in Psoriasis and Psoriatic Arthritis

    M. Elaine Husni1,2, Anthony Fernandez1, Rakesh Singh3, Brett Hauber4, Jessie Sutphin4, Joshua Posner4 and Arijit Ganguli3, 1Cleveland Clinic, Cleveland, OH, 2Rheumatology Dept A50, Cleveland Clinic Foundation, Cleveland, OH, 3AbbVie Inc., North Chicago, IL, 4RTI Health Solutions, Research Triangle Park, NC

    Background/Purpose: Psoriasis and psoriatic arthritis arise from the same immune system response but result in different symptoms and impacts on daily activities. A patient with…
  • Abstract Number: 2693 • 2017 ACR/ARHP Annual Meeting

    Relationships between Levels of Patient Activation, Self-Efficacy, and Demographic Variables in Systemic Sclerosis

    Janet L. Poole1, Veronica J. Berrocal2, Jennifer Serrano3, Erica Bush3 and Dinesh Khanna3, 1Health Sciences Ctr OT Program, 1 University of New Mexico, Albuquerque, NM, 2Div of Rheumatology, University of Michigan, Ann Arbor, MI, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Patient activation refers to the ability and confidence people have to be engaged in managing their health care [Hibbard, 2004]. Knowledge and beliefs about…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 9
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology